Medicenna Therapeutics Corp. Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.

MDNA

Rank in Stocks #25703
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and... Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent glioblastoma and is also being investigated for other brain and non-brain tumor types in earlier developmental stages. The company's pipeline also includes MDNA11, an improved IL-2 variant designed to stimulate immune responses against cancer; MDNA209, an IL-2 antagonist aimed at autoimmune conditions like multiple sclerosis and graft-versus-host disease; MDNA413, a dual IL-4/IL-13 antagonist for use in cancer immunotherapy; and MDNA132, an IL-13 Superkine targeting solid tumors. Furthermore, Medicenna utilizes its BiSKITs platform to engineer bespoke Superkines by joining them with proteins, antibodies, cytokines, or other Superkines. The company's main office is located in Toronto, Canada.
Share Price
$0.26982704
Last synced: 2026-11-13
Market Cap
$23.38M
Change (1 day)
-1.40%
Change (1 year)
-72.24%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Trade Medicenna Therapeutics Corp. (MDNA)

Category

Healthcare
EPS for Medicenna Therapeutics Corp. (MDNA)
EPS as of June 2026 TTM: $-0.15
According to Medicenna Therapeutics Corp.'s latest financial reports, its current EPS (TTM) is $-0.15. At the end of 2025 the company had an EPS of $-0.10, an increase over its 2024 EPS of $-0.27.
EPS history for Medicenna Therapeutics Corp. from 2014 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.15 54.20%
2025 $-0.10 -61.89%
2024 $-0.27 -1,644.63%
2023 $0.02 -105.27%
2022 $-0.34 20.65%
2021 $-0.28 50.79%
2020 $-0.18 37.02%
2019 $-0.13 -43.93%
2018 $-0.24 -28.85%
2017 $-0.34 426.32%
2016 $-0.06 52.49%
2015 $-0.04 -5.18%
2014 $-0.04 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 477.17%
US
$15.66 -10,255.64%
US
$-7.07 4,484.95%
US
$-5.29 3,330.61%
AU
$12.73 -8,356.94%
BE

Questions about Medicenna Therapeutics Corp.'s earnings per share (EPS)

What is Medicenna Therapeutics Corp.'s earnings per share (EPS)?

Medicenna Therapeutics Corp.'s earnings per share (EPS) over the last twelve months is $-0.15, as of Jun 2026.

What was Medicenna Therapeutics Corp.'s earnings per share (EPS) in 2025?

In 2025, Medicenna Therapeutics Corp.'s earnings per share (EPS) was $-0.10, compared with $-0.27 in 2024.

How has Medicenna Therapeutics Corp.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Medicenna Therapeutics Corp.'s earnings per share (EPS) was highest in 2023 ($0.02) and lowest in 2022 ($-0.34).

How does Medicenna Therapeutics Corp.'s earnings per share (EPS) compare with similar companies?

Medicenna Therapeutics Corp.'s earnings per share (EPS) ($-0.15) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.